Vanguard Capital Management
SRPT icon

Vanguard Capital Management’s Sarepta Therapeutics SRPT Stock Holding History

Vanguard Capital Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$82.5M Buy
4,591,755
+13,520
+0.3% +$256K ﹤0.01% 1665
2026
Q1 		$99.6M Buy
+4,578,235
New +$88.6M ﹤0.01% 1468

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Capital Management's SRPT Position: Q2 2026 in Review

Vanguard Capital Management increased its Sarepta Therapeutics (SRPT) stake by 0.3% in Q2 2026, buying an estimated $256K and bringing the position to 4,591,755 shares worth $82.5M. The position accounts for ﹤0.01% of the portfolio, ranked #1665.

Vanguard Capital Management first reported a position in SRPT in Q1 2026 and has held it in 2 quarters since. The position peaked at $99.6M in Q1 2026. 320 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • Vanguard Capital Management held 4,591,755 shares of Sarepta Therapeutics worth $82.5M as of Q2 2026.
  • Vanguard Capital Management bought 13,520 Sarepta Therapeutics shares in Q2 2026, an estimated $256K.
  • Sarepta Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #1665 holding.
  • Vanguard Capital Management first reported a position in Sarepta Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Capital Management's Sarepta Therapeutics position peaked at $99.6M in Q1 2026.
  • 320 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.